Skip to main content

Advertisement

SpringerLink
Log in

Lung cancer in never smokers: a different disease

  • Lung Cancer (C Mascaux, Section Editor)
  • Published:
Current Respiratory Care Reports Aims and scope Submit manuscript

Abstract

Lung cancer in never smokers (LCINS) is often considered a different disease entity with a distinct molecular sub-classification. Notably, actionable mutations in epidermal growth factor receptor (EGFR), v-Ki-ras2 Kirsten Rat sarcoma viral oncogene homolog (KRAS) and anaplastic lymphoma kinase (ALK)-rearrangement are three major recurrent oncogenic alterations in LCINS. HER2 and BRAF mutations, ROS1 and RET rearrangements are also included, although these are known to occur with low frequencies. Although the overall response rate (ORR) to EGFR tyrosine kinase inhibitors (TKIs) in unselected patients was only 10 %, subgroup analyses revealed comparatively higher response rates and survival in women, never smokers and Asians harbouring EGFR mutations, suggesting a predictive and/or prognostic significance among patients with mutated EGFR by smoking status. Differences in the prevalence of KRAS mutations between subgroups have also been described: 8 % of never smokers versus 57 % of former/current smokers with lung adenocarcinoma harbour KRAS mutations, and although 3 % to 5 % of unselected patients with lung adenocarcinoma have ALK rearrangements, the frequency appears to be more pronounced in never smokers. There is a suggestion that prognostic and predictive relevance of KRAS mutations varies by smoking status, but it is still less characterized as well as the smoking-related prognostic and predictive value of ALK rearrangement and the other alterations, which are still largely unknown. Clinical trials of lung cancer patients should always be stratified by smoking history and the identification of differences according to smoking status may help optimize future targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Parkin DM et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  3. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001;31(2–3):139–48.4.

    Article  CAS  PubMed  Google Scholar 

  4. Thun MJ et al. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst. 2006;98:691–9.

    Article  PubMed  Google Scholar 

  5. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers- a different disease. Nat Rev Cancer. 2007;7:778–90.

    Article  CAS  PubMed  Google Scholar 

  6. Thun MJ, Henley SJ, Calle EE. Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene. 2002;21:7307–25.

    Article  CAS  PubMed  Google Scholar 

  7. Toh CK et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006;24:2245–51.

    Article  PubMed  Google Scholar 

  8. Fei G et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006;24(15):2245–51.

    Article  Google Scholar 

  9. Ou SH. Lung cancer in never smokers. Does smoking matter in the era of molecular diagnostics and targeted therapy? J Clin Pathol. 2013;66:839–46.

    Article  PubMed  Google Scholar 

  10. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007;25(5):561–70.

    Article  PubMed  Google Scholar 

  11. Rikova K et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–203.

    Article  CAS  PubMed  Google Scholar 

  12. Thun MJ et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med. 2008;5(9):e185.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.

    Article  CAS  PubMed  Google Scholar 

  14. Toh CK et al. The impact of smoking status behaviour and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest. 2004;126:1750–6.

    Article  PubMed  Google Scholar 

  15. Toh CK et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006;24:2245–51.

    Article  PubMed  Google Scholar 

  16. Shimizu H et al. Comparison of clinico-epidemiological features of lung cancer patients with and without a history of smoking. Jpn J Clin Oncol. 1984;14:595–600.

    CAS  PubMed  Google Scholar 

  17. Wakelee HA et al. Lung cancer incidence in never smokers. J Clin Oncol. 2007;25(5):472–8.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Foeglé J et al. Specific features of non-small cell lung cancer in women: a retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997. J Thorac Oncol. 2007;2(6):466–74.

    Article  PubMed  Google Scholar 

  19. Blanchon F et al. Epidemiologic of primary bronchial carcinoma management in the general French hospital centers. Rev Mal Respir. 2002;19(6):727–34.

    CAS  PubMed  Google Scholar 

  20. Couraud S et al. The BioCAST / IFCT-1002 study: a comprehensive overview of demographic, risk exposure and somatic mutations of non-small cell lung cancer occurring among French never smokers. Abstract O18.03. Sydney: 15th World Conference on Lung Cancer; 2013.

    Google Scholar 

  21. Kawaguchi T et al. Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan. J Thorac Oncol. 2010;5(7):1011–7.

    PubMed  Google Scholar 

  22. Bofetta P et al. Incidence of lung cancer in a large cohort of non-smoking men from Sweden. Int J Cancer. 2001;94(4):591–3.

    Article  Google Scholar 

  23. McCarthy WJ et al. Lung cancer in never smokers epidemiology and risk prediction models. Risk Anal. 2012;32(Suppl1):S69–84.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Govindan R et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150:1121–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Jen J et al. Oncogene mutations and novel transcript fusions in lung adenocarcinoma from never smokers. Abstract O04.04. Sydney: 15th World Conference on Lung Cancer; 2013.

    Google Scholar 

  26. Lan Q et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet. 2012;44(12):1330–5.

    Article  CAS  PubMed  Google Scholar 

  27. Kim JH et al. Genome wide association study of lung cancer in Korean non-smoking women. J Korean Med Sci. 2013;28:840–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Kim SC et al. A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers. PLoS ONE. 2013;8(2):e55596.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Wu X et al. Genome-wide association study of genetic predictors of overall survival for non–small cell lung cancer in never smokers. Cancer Res. 2013;73(13):4028–38. Few studies have comprehensively examined the influence of genetic variants on lung cancer survival and have been carried out primarily on smoker patients. In this study the authors conducted the first Genome Wide Association Study among never smoker patients with lung cancer to identify genetic variants that are associated with overall survival.

    Article  CAS  PubMed  Google Scholar 

  30. Fernandez-Cuesta L et al. Identification of CD74–NRG1, a new recurrent fusion gene in invasive mucinous lung adenocarcinomas of never smokers. Abstract O04.01. Sydney: 15th World Conference on Lung Cancer; 2013.

    Google Scholar 

  31. Paez JG et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.

    Article  CAS  PubMed  Google Scholar 

  32. Pham D et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006;10(24):1700–4.

    Article  Google Scholar 

  33. Mitsudomi T et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8.

    Article  CAS  PubMed  Google Scholar 

  34. Inoue A et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54–9.

    Article  CAS  PubMed  Google Scholar 

  35. Zhou C et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.

    Article  CAS  PubMed  Google Scholar 

  36. Rosell R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.

    Article  CAS  PubMed  Google Scholar 

  37. Sequist LV et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.

    Article  CAS  PubMed  Google Scholar 

  38. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–25.

    Article  Google Scholar 

  39. Hata A et al. How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? J Thorac Oncol. 2013;8(1):89–95.

    Article  CAS  PubMed  Google Scholar 

  40. Paik PK et al. Clinical characteristics of patients with lung adenocarcinoma harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046–51.

    Article  PubMed  Google Scholar 

  41. Stephens P et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431(7008):525–6.

    Article  CAS  PubMed  Google Scholar 

  42. Li T et al. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31:1039–49. This review summarizes current status, evolution, challenges and opportunities for clinical application of genotyping and genomic tests in therapeutic decision making for NSCLC. This represents the first of a series of steps to improve knowledge on molecular genetics on lung cancer and subsequently in particular subpopulations, in order to design more and more specific clinical trials.

    Article  CAS  PubMed  Google Scholar 

  43. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175–80.

    Article  CAS  PubMed  Google Scholar 

  44. Mazières J et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997–2003.

    Article  PubMed  Google Scholar 

  45. Cappuzzo F et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho- akt-positive or never smoker patients with advanced non-small-cell lung cancer: the oncobell trial. J Clin Oncol. 2007;25(16):2248–55.

    Article  CAS  PubMed  Google Scholar 

  46. Riely GJ et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14:5731–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Dogan S et al. Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18(22):6169–77.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Ahrendt SA et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92:1525–30.

    Article  CAS  PubMed  Google Scholar 

  49. Yu HA et al. Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13. J Clin Oncol. 2013;31:8025.

    Google Scholar 

  50. Paik PK et al. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer. 2012;118(23):5840–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Pratlias CA et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008;68:9375–83.

    Article  Google Scholar 

  52. Youssem SA et al. The histopathology of BRAF- V600E- mutated lung adenocarcinoma. Am J Surg Pathol. 2008;63:315–21.

    Google Scholar 

  53. Marchetti A et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574–9.

    Article  CAS  PubMed  Google Scholar 

  54. An T et al. Clinical features with lung adenocarcinoma harboring BRAF V600E mutations. J Clin Oncol. 2013;31:8101.

    Article  Google Scholar 

  55. Shaw AT et al. Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–53.

    Article  CAS  PubMed  Google Scholar 

  56. Camidge DR et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;10:1011–9.

    Article  Google Scholar 

  57. Kim DW et al. Results of a global phase II study with crizotinib in ALK-positive NSCLC. J Clin Oncol. 2012;30:7533.

    Google Scholar 

  58. Shaw AT et al. Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (PROFILE 1007). Ann Oncol. 2012;23 Suppl 9:LBA1.

    Google Scholar 

  59. Kubo A et al. Impact of environmental tobacco smoke (ETS) on ALK rearrangements in never smokers (NS) with non-small cell lung cancer (NSCLC): analyses on a prospective multinational ETS registry. J Clin Oncol. 2013;31:7565.

    Google Scholar 

  60. Kubo A et al. Impacts of environmental tobacco smoke on EGFR mutations and ALK rearrangements in never smokers with non-small cell lung cancer: Analyses on a prospective multinational ETS registry. Abstract O18.02. Sydney: 15th World Conference on Lung Cancer; 2013.

    Google Scholar 

  61. Yoshida A et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol. 2013;37(4):554–62.

    Article  PubMed  Google Scholar 

  62. Bergethon K et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–70.

    Article  CAS  PubMed  Google Scholar 

  63. Takeuchi K et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–81.

    Article  CAS  PubMed  Google Scholar 

  64. Li C et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One. 2011;6(11):e28204.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Rimkunas VM et al. Analysis of receptor tyrosine kinase ROS1- positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18(16):4449–57.

    Article  CAS  PubMed  Google Scholar 

  66. Kim HR et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol. 2013;24:2364–70.

    Article  CAS  PubMed  Google Scholar 

  67. Cai W et al. ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann Oncol. 2013;24:1822–7.

    Article  CAS  PubMed  Google Scholar 

  68. Wang R et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012;30(35):4352–9.

    Article  CAS  PubMed  Google Scholar 

  69. Bennati C et al. Identification of targetable driver mutations in molecularly selected never smoker lung adenocarcinomas. Abstract P 1.02–006. Sydney: 15th World Conference on Lung Cancer; 2013.

    Google Scholar 

  70. Go H et al. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 2010;5(3):305–13.

    Article  PubMed  Google Scholar 

  71. Varghese AM et al. Small cell lung cancer (SCLC) among patients who are never smokers. J Clin Oncol. 2013;31:7593.

    Article  Google Scholar 

  72. Sheperd FA et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353:123–32.

    Article  Google Scholar 

  73. Thatcher N et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled. Multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–37.

    Article  CAS  PubMed  Google Scholar 

  74. Kawaguchi T et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer. J Thorac Oncol. 2010;5(5):620–30.

    PubMed  Google Scholar 

  75. Janjigian YY et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV non small cell lung cancer. Cancer. 2010;116(3):670–5.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflicts of Interests

Tiziana Vavalà, Matteo Giaj Levra, and Silvia Novello declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Oncology, University of Torino, Regione Gonzole 10, 10043, Orbassano, TO, Italy

    Tiziana Vavalà, Matteo Giaj Levra & Silvia Novello

Authors
  1. Tiziana Vavalà
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matteo Giaj Levra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Silvia Novello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Novello.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vavalà, T., Giaj Levra, M. & Novello, S. Lung cancer in never smokers: a different disease. Curr Respir Care Rep 3, 26–34 (2014). https://doi.org/10.1007/s13665-013-0071-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13665-013-0071-z

Keywords

Search

Navigation